Markets DMAC

Wednesday 4/12 Insider Buying Report: DMAC, COSM

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

On Monday, DiaMedica Therapeutics' Chief Business Officer, David J. Wambeke, made a $750,000 purchase of DMAC, buying 468,750 shares at a cost of $1.60 each. Wambeke was up about 15.6% on the buy at the high point of today's trading session, with DMAC trading as high as $1.85 in trading on Wednesday. DiaMedica Therapeutics is trading up about 11.1% on the day Wednesday.

And on Friday, Chief Executive Officer Grigorios Siokas purchased $54,540 worth of Cosmos Health, purchasing 2,238 shares at a cost of $24.37 each. Before this latest buy, Siokas made one other purchase in the past twelve months, buying $3.00M shares at a cost of $11.50 each. Cosmos Health is trading up about 3.9% on the day Wednesday. Investors can snag COSM even cheaper than Siokas did, with the stock changing hands as low as $3.40 in trading on Wednesday -- that's 86.0% below Siokas's purchase price.

{{ InlineImage1 }}VIDEO: Wednesday 4/12 Insider Buying Report: DMAC, COSM

BNK Invest
BNK Invest Inc. provides investment services and information. BNK Invest owns and operates a market news family of websites including DividendChannel, ETFChannel, StockOptionsChannel, and others, which make up an investor community featuring stock message boards, ratings, research, and strategies. BNK Invest caters to investing firms and individual investors internationally.
10 Bargains You Can Buy Cheaper Than Insiders Did 10 Stocks Crossing Below Book Value 10 Oversold Stocks You Need To Know About More articles by this source
Stocks Mentioned

Latest Articles

Data is currently not available